XML 53 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Data (Tables)
 6 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Reportable Segment
Selected information by reportable segment was as follows:

Three Months Ended
 
Six Months Ended

June 30,
2017

June 24,
2016
 
June 30,
2017
 
June 24,
2016
Net sales:



 
 
 
 
Specialty Brands
$
594.5


$
589.3

 
$
1,151.7

 
$
1,124.3

Specialty Generics
216.0

 
263.4

 
454.6

 
527.8

Net sales of reportable segments
810.5


852.7

 
1,606.3

 
1,652.1

Other (1)
14.0


13.9

 
29.1

 
30.3

Net sales
$
824.5


$
866.6

 
$
1,635.4

 
$
1,682.4

Operating income:



 
 
 
 
Specialty Brands
$
274.1


$
302.1

 
$
549.1

 
$
563.0

Specialty Generics
63.3

 
98.1

 
139.5

 
197.0

Segment operating income
337.4


400.2

 
688.6

 
760.0

Unallocated amounts:





 
 
 
 
Corporate and unallocated expenses (2)          
(49.1
)

(34.1
)
 
(116.3
)
 
(59.5
)
Intangible asset amortization
(174.7
)

(175.8
)
 
(349.8
)
 
(350.8
)
Restructuring and related charges, net (3)
(1.5
)

(15.2
)
 
(20.2
)
 
(25.3
)
Non-restructuring impairment charges
—

 
—

 
—

 
(16.9
)
Operating income
$
112.1

 
$
175.1

 
$
202.3

 
$
307.5


(1)
Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.
(2)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
(3)
Includes restructuring-related accelerated depreciation.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's reportable segments are as follows:
 
Three Months Ended
 
Six Months Ended
 
June 30,
2017
 
June 24,
2016
 
June 30,
2017
 
June 24,
2016
Acthar
$
319.4

 
$
298.3

 
$
591.2

 
$
546.7

Inomax
125.5

 
121.1

 
253.9

 
236.6

Ofirmev
75.7

 
70.7

 
149.1

 
141.8

Therakos immunotherapy
51.2

 
52.5

 
102.4

 
102.7

Hemostasis products
13.5

 
13.9

 
26.6

 
25.3

Other
9.2

 
32.8

 
28.5

 
71.2

Specialty Brands
594.5

 
589.3

 
1,151.7

 
1,124.3

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
23.0

 
38.2

 
53.3

 
79.0

Oxycodone (API) and oxycodone-containing tablets
25.1

 
30.6

 
47.2

 
68.5

Methylphenidate ER
20.2

 
24.3

 
43.9

 
48.9

Other controlled substances
107.7

 
124.7

 
215.1

 
246.6

Other products
40.0

 
45.6

 
95.1

 
84.8

Specialty Generics
216.0

 
263.4

 
454.6

 
527.8

 
 
 
 
 
 
 
 
Other (1)
14.0

 
13.9

 
29.1

 
30.3

Net sales
$
824.5

 
$
866.6

 
$
1,635.4

 
$
1,682.4


(1)
Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.